Five Eleven Pharma, Inc. Report issue

For profit Phase 1
Founded: Philadelphia PA United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2016
NCT02826382
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Five Eleven Pharma, Inc.

Active Ingredients

Drugs in Phase 1 Trials (4)

68ga p15-041 (1 trial)

p16-093 (2 trials)

p16-129 (1 trial)

p17-059 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Bone Marrow Diseases (Phase 1)

Bone Neoplasms (Phase 1)

Carcinoma, Renal Cell (Phase 1)

Kidney Neoplasms (Phase 1)

Neoplasm Metastasis (Phase 1)

Parkinson Disease (Phase 1)

Prostatic Neoplasms (Phase 1)

Recurrence (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 4